Skip to main content
Premium Trial:

Request an Annual Quote

Amoy Dx Partners With Canbridge on CDx Development

NEW YORK (GenomeWeb) – Amoy Diagnostics today announced a deal with biopharmaceutical firm Canbridge Life Sciences to develop a companion diagnostic for Canbridge's lead product, CAN008.

Amoy will supply its CD95 IHC and CpG2 qPCR kits as part of the deal. CAN008 is a fully human Fc fusion protein, and in a previous Phase II trial conducted in Europe, it demonstrated "significant overall survival benefit" for recurrent glioblastoma multiforme patients with high expression of the CD95 ligand, or low methylation of CD95L promotor CpG2, the companies said.

CAN008 is in a Phase I/II clinical study in Taiwan and Canbridge intends to initiate a Phase II trial in China in 2018. Patients will be screened for the CAN008 biomarker to determine trial enrollment eligibility.

Terms of the deal were not disclosed.